All conditions

Alzheimer's Disease

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

99
Trials tracked
2
Recruiting now
34
Australian sites
46
Countries
Country

Showing 99 trials

🇦🇺 AU site

Trial: NCT05345509 — Inventage Lab., Inc.

NCT05345509 · Inventage Lab., Inc.
Active, Not Recruiting Phase 2 Est. completion 13 November 2025
🇦🇺 AU

**Who might be able to join this trial:** - You are a generally healthy man or woman between 18 and 55 years old. - You are a non-smoker or only smoke occasionally (fewer than 10 cigarettes or the nicotine equivalent per week), and you are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06544616 — Janssen Pharmaceutica N.V., Belgium

NCT06544616 · Janssen Pharmaceutica N.V., Belgium
Active, Not Recruiting Phase 2 Est. completion 22 December 2026
🇦🇺 AU 🇧🇪 BE 🇫🇷 FR 🇩🇪 DE 🇯🇵 JP

**Who might be able to join this trial:** - A brain scan (called a tau PET scan) has shown an elevated level of a protein called tau, which is associated with Alzheimer's disease, above a certain threshold - You currently have no signs of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06653153 — Eli Lilly and Company

NCT06653153 · Eli Lilly and Company
Active, Not Recruiting Phase 3 Est. completion 1 April 2029
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇯🇵 JP Puerto Rico

**Who might be able to join this trial:** - You have had a specific blood or fluid test (measuring a protein called phosphorylated tau) that suggests the presence of Alzheimer's-related changes in the brain. - You have a reliable person (su...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06291909 — University of South Australia

NCT06291909 · University of South Australia
Active, Not Recruiting Not Applicable Est. completion 28 February 2026
🇦🇺 AU

**Who might be able to join this trial:** - You are aged 65 years or older - You live independently in the community (not in a care home or similar facility) - You can speak and understand English well enough to complete thinking and memory...

🇦🇺 AU site

Trial: NCT04639050 — Hoffmann-La Roche

NCT04639050 · Hoffmann-La Roche
Active, Not Recruiting Phase 2 Est. completion 31 July 2027
🇦🇺 AU 🇨🇦 CA 🇨🇱 CL 🇯🇵 JP 🇵🇱 PL

**Who might be able to join this trial:** - You are able to give written consent to participate in the study yourself - You have a "study partner" (such as a family member or close friend) who agrees to take part, has regular contact with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01266525 — Sanofi

NCT01266525 · Sanofi
Completed Phase 2 Est. completion 1 January 2013
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed specifically with Alzheimer's Disease (not dementia caused by strokes or other conditions). - You have been taking donepezil (either 5 mg or 10 mg daily) at a steady, well-tole...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02727699 — Actinogen Medical

NCT02727699 · Actinogen Medical
Completed Phase 2 Est. completion 15 March 2019
🇦🇺 AU 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You are 50 years of age or older - You have been diagnosed with mild Alzheimer's disease, with signs of getting worse in the 6 months before screening, as confirmed by your doctor using recognise...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02006654 — H. Lundbeck A/S

NCT02006654 · H. Lundbeck A/S
Completed Phase 3 Est. completion 1 January 2017
🇦🇺 AU 🇧🇷 BR 🇨🇿 CZ 🇩🇪 DE 🇮🇱 IL

Who might be able to join this trial: - You have a caregiver who knows you well and can be relied upon to support you. - You are living at home or in the community (not currently staying in a hospital). - You have been diagnosed with Alzhei...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00471211 — Prana Biotechnology Limited

NCT00471211 · Prana Biotechnology Limited
Completed Phase 2 Est. completion 1 December 2007
🇦🇺 AU 🇸🇪 SE

Who might be able to join this trial: - You have been diagnosed with what doctors believe is early Alzheimer's disease - You are already taking a specific type of Alzheimer's medication (called an acetylcholinesterase inhibitor) at a steady...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00104013 — Sanofi

NCT00104013 · Sanofi
Completed Phase 3 Est. completion 1 November 2007
🇦🇺 AU 🇫🇷 FR Hong Kong 🇮🇹 IT 🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with probable Alzheimer's disease (based on standard medical guidelines) - Your Alzheimer's is considered mild to moderate, shown by a score of 16 to 26 on a standard memor...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04745104 — Atridia Pty Ltd.

NCT04745104 · Atridia Pty Ltd.
Completed Phase 1 Est. completion 21 March 2022
🇦🇺 AU

**Who might be able to join this trial:** - You are able to understand the trial procedures and any possible side effects, and you are willing to take part voluntarily - You are between 18 and 45 years old (for Part 1 of the trial) or betw...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00459550 — GlaxoSmithKline

NCT00459550 · GlaxoSmithKline
Completed Phase 1 Est. completion 30 May 2011
🇦🇺 AU 🇳🇴 NO 🇸🇪 SE

**Who might be able to join this trial:** - You have been diagnosed by a doctor as probably having Alzheimer's disease (AD). - Your Alzheimer's is considered mild, based on a standard memory and thinking test score between 18 and 26. - You...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05792163 — SciNeuro

NCT05792163 · SciNeuro
Completed Phase 1 Est. completion 29 November 2023
🇦🇺 AU

**Who might be able to join this trial:** - You must be 18 years of age or older at the time you sign the consent form. - You must be considered generally healthy by the study doctor, based on a physical check-up, medical history, vital si...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00884507 — Hoffmann-La Roche

NCT00884507 · Hoffmann-La Roche
Completed Phase 2 Est. completion 1 November 2010
🇦🇷 AR 🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You must be 50 years of age or older - You must have been diagnosed with probable Alzheimer's disease - You must have scored between 13 and 22 on a standard memory and thinking test called the MMSE (c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00455000 — Pfizer

NCT00455000 · Pfizer
Completed Phase 1 Est. completion 1 September 2009
🇦🇺 AU 🇨🇦 CA 🇸🇪 SE 🇬🇧 GB

**Who might be able to join this trial:** - You are male, or a female who is not able to become pregnant (for example, post-menopausal), and you are between 50 and 85 years old - You have been diagnosed with probable Alzheimer's disease, co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00297414 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT00297414 · Johnson & Johnson Pharmaceutical Research & Develo...
Completed Not Applicable Est. completion 1 January 2005
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇨🇦 CA

Who might be able to join this trial: - You must have already taken part in one of three specific previous studies (known as CR003145, CR002014, or CR005947), where you were given either galantamine or a placebo (a dummy treatment). Who ma...

🇦🇺 AU site

Trial: NCT00151398 — Wyeth is now a wholly owned subsidiary of Pfizer

NCT00151398 · Wyeth is now a wholly owned subsidiary of Pfizer
Completed Phase 2 Est. completion 15 March 2008
🇦🇷 AR 🇦🇺 AU 🇨🇦 CA 🇿🇦 ZA 🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with probable Alzheimer's disease based on standard medical criteria. - You are able to give your own consent to take part, and your caregiver must also agree to participate in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04491006 — LeonaBio

NCT04491006 · LeonaBio
Completed Phase 2 Est. completion 20 May 2022
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You are between 55 and 85 years old - You have been diagnosed with mild-to-moderate Alzheimer's disease dementia, based on recognised medical guidelines - Your memory and thinking scores fall wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00829374 — Medivation, Inc.

NCT00829374 · Medivation, Inc.
Completed Phase 3 Est. completion 1 December 2011
🇦🇺 AU 🇧🇪 BE 🇫🇮 FI 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with mild-to-moderate Alzheimer's disease. - Your Alzheimer's diagnosis meets a specific standard set of medical guidelines known as DSM-IV-TR criteria (confirm with trial site...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01138111 — Lantheus Biosciences Ltd.

NCT01138111 · Lantheus Biosciences Ltd.
Completed Phase 1 Est. completion 1 December 2011
🇦🇺 AU

**Who might be able to join this trial:** - You have been found to have mild memory or thinking problems on formal tests, but do not have dementia or major difficulties with daily activities. - You do not have any serious medical or neurolo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07033494 — Merck Sharp & Dohme LLC

NCT07033494 · Merck Sharp & Dohme LLC
Recruiting Phase 2 Est. completion 30 April 2029
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇯🇵 JP

**Who might be able to join this trial:** - You have been diagnosed with mild memory or thinking problems (mild cognitive impairment) or mild dementia caused by Alzheimer's disease - You have a trusted person (such as a family member or clo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06947941 — Bristol-Myers Squibb

NCT06947941 · Bristol-Myers Squibb
Recruiting Phase 3 Est. completion 21 February 2028
🇦🇺 AU 🇨🇦 CA 🇯🇵 JP 🇬🇧 GB 🇺🇸 US

Who might be able to join this trial: - You must be between 55 and 90 years old at the time of your first screening visit. - You must have been diagnosed with Alzheimer's disease based on the most recent 2024 Alzheimer's Association guideli...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05575076 — Cassava Sciences, Inc.

NCT05575076 · Cassava Sciences, Inc.
Terminated Phase 3 Est. completion 31 January 2025
🇦🇺 AU 🇨🇦 CA Puerto Rico 🇰🇷 KR 🇺🇸 US

Who might be able to join this trial: - You must have already completed one of two specific earlier studies called RETHINK-ALZ or REFOCUS-ALZ. - You still show signs and symptoms that are consistent with Alzheimer's disease. - You have a st...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03352557 — Biogen

NCT03352557 · Biogen
Terminated Phase 2 Est. completion 30 August 2021
🇦🇺 AU 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT 🇯🇵 JP

**Who might be able to join this trial:** - You have experienced a slow, gradually worsening change in memory that has been happening for more than 6 months. - You have been diagnosed with mild cognitive impairment (MCI) or mild Alzheimer'...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00996918 — Pfizer

NCT00996918 · Pfizer
Terminated Phase 3 Est. completion 1 November 2012
🇦🇺 AU 🇧🇪 BE 🇨🇱 CL 🇫🇮 FI 🇫🇷 FR

Who might be able to join this trial: - You must have already completed a specific earlier study called "3133K1-3000" and had a brain scan (MRI) that confirmed a diagnosis of Alzheimer's disease - You must score 10 or higher on a standard m...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02245568 — TauRx Therapeutics Ltd

NCT02245568 · TauRx Therapeutics Ltd
Terminated Phase 3 Est. completion 1 May 2017
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇭🇷 HR 🇫🇮 FI

**Who might be able to join this trial:** - You must have already completed participation in one of three specific earlier TauRx research studies (TRx-237-005, TRx-237-008, or TRx-237-015) for dementia or probable Alzheimer's disease, incl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01524887 — Baxalta now part of Shire

NCT01524887 · Baxalta now part of Shire
Terminated Phase 3 Est. completion 16 July 2013
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇯🇵 JP 🇵🇱 PL

**Who might be able to join this trial:** - You are between 50 and 89 years old (inclusive) - You (or your legal representative) are able to give written consent to take part - You have a caregiver who is willing and able to give written c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04619420 — Janssen Research & Development, LLC

NCT04619420 · Janssen Research & Development, LLC
Terminated Phase 2 Est. completion 17 October 2025
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇯🇵 JP

**Who might be able to join this trial:** - You have been gradually and progressively experiencing memory or thinking problems for at least the past 6 months, confirmed by both you and someone who knows you well, and your memory difficulti...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02670083 — Hoffmann-La Roche

NCT02670083 · Hoffmann-La Roche
Terminated Phase 3 Est. completion 31 May 2019
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You weigh between 40 and 120 kilograms (about 88 to 265 pounds) - You have someone in your life (like a family member or close friend) who sees you regularly, can accurately describe your memory a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05256134 — Hoffmann-La Roche

NCT05256134 · Hoffmann-La Roche
Terminated Phase 3 Est. completion 13 March 2023
🇦🇷 AR 🇦🇺 AU 🇨🇦 CA 🇮🇹 IT 🇵🇱 PL

**Who might be able to join this trial:** - You are willing and able to take part in all parts of the study, including memory and thinking tests, physical and brain exams, MRI scans, spinal fluid collection, genetic testing, and PET scans....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05028114 — Cerecin

NCT05028114 · Cerecin
Terminated Phase 1 Est. completion 18 March 2022
🇦🇺 AU

Who might be able to join this trial: - You must be between 18 and 65 years old at the time of signing the consent form. - You must be considered generally healthy, based on a doctor's review of your medical history, physical exam, blood te...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02791191 — Eli Lilly and Company

NCT02791191 · Eli Lilly and Company
Terminated Phase 2 Est. completion 2 July 2018
🇦🇺 AU 🇨🇦 CA 🇯🇵 JP 🇺🇸 US

**Who might be able to join this trial:** - A qualified doctor has diagnosed you with mild Alzheimer's disease dementia based on recognised medical guidelines. - You scored between 20 and 26 (inclusive) on a standard memory and thinking tes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02972658 — AstraZeneca

NCT02972658 · AstraZeneca
Terminated Phase 3 Est. completion 2 October 2018
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You must have already taken part in a previous clinical trial called AMARANTH (NCT02245737) and still meet the requirements to continue into this new phase of the study. Who may not be able to join:...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06114914 — University of Tasmania

NCT06114914 · University of Tasmania
UNKNOWN Not Applicable Est. completion 1 June 2025
🇦🇺 AU

**Who might be able to join this trial:** *For the first two parts of the study (Aims 1 & 2):* - You are over 50 years old and already taking part in the ISLAND Project - You have already given a blood sample as part of the ISLAND Project...

Trial: NCT05027789 — University of California, Davis

NCT05027789 · University of California, Davis
Active, Not Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

Who might be able to join this trial: - You are 65 years of age or older - You speak English - You have noticed that your memory or thinking has gotten worse over the last 1–3 years and feel this is worse than others your age, but a standar...

Trial: NCT05997784 — University Hospital, Montpellier

NCT05997784 · University Hospital, Montpellier
Active, Not Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: - The child must be starting the school year at the CM1 grade level (roughly age 9-10 in the French school system) - The child must be in a classroom that has been chosen to take part in this project -...

Trial: NCT04840979 — Columbia University

NCT04840979 · Columbia University
Active, Not Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 50 years of age or older - You have been diagnosed with mild memory problems (mild cognitive impairment) or Alzheimer's disease, OR you have no memory or thinking problems at all - If you...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04075435 — Mclean Hospital

NCT04075435 · Mclean Hospital
Active, Not Recruiting Early Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with probable Alzheimer's disease or mild cognitive impairment (MCI) - You scored between 15 and 30 (inclusive) on a standard memory and thinking test called the MMSE - You...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05768425 — Danish Dementia Research Centre

NCT05768425 · Danish Dementia Research Centre
Active, Not Recruiting Not Applicable Est. completion 1 December 2032
🇩🇰 DK

Who might be able to join this trial: **As a healthy volunteer:** - You are between 18 and 40 years old - You are able to follow instructions and participate, as assessed by the lead researcher - You are able to understand and sign a conse...

Trial: NCT05731440 — Washington University School of Medicine

NCT05731440 · Washington University School of Medicine
Active, Not Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Men or women of any race - Adults aged 18 or older - People who are generally healthy, or people who have been diagnosed with Alzheimer's disease **Who may not be able to join:** - People who hav...

Trial: NCT04289389 — Norwegian Centre for Ageing and Health

NCT04289389 · Norwegian Centre for Ageing and Health
Completed Not Applicable Est. completion 7 April 2026
🇳🇴 NO

Who might be able to join this trial: - You must live in the specific geographic area designated by the trial. Who may not be able to join: - There are no stated exclusion criteria for this trial. Important: Always verify eligibility with...

Trial: NCT02820896 — Genentech, Inc.

NCT02820896 · Genentech, Inc.
Completed Phase 1 Est. completion 26 June 2017
🇺🇸 US

**Who might be able to join this trial:** **For all participants:** - Your total body weight is between 45 and 120 kilograms (roughly 99 to 265 pounds) - You agree not to donate blood or blood products for the entire study and for 1 year a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02720445 — University of Southern California

NCT02720445 · University of Southern California
Completed Phase 2 Est. completion 25 August 2025
🇺🇸 US

**Who might be able to join this trial:** - You (or someone close to you, or your doctor) have noticed that your memory is not as good as it used to be - You scored below a certain level on a standard memory test, based on how many years o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02646982 — Emory University

NCT02646982 · Emory University
Completed Phase 2 Est. completion 17 August 2020
🇺🇸 US

**Who might be able to join this trial:** - You have been told you have Mild Cognitive Impairment (MCI), meaning you have noticed memory problems yourself, and tests have confirmed your memory is below the expected level for your years of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03080051 — Molecular NeuroImaging

NCT03080051 · Molecular NeuroImaging
Completed Early Phase 1 Est. completion 6 March 2017
🇺🇸 US

**Who might be able to join this trial:** **For everyone:** - You must be willing and able to sign a consent form before any part of the study begins. - Women must either be surgically sterile (e.g., had a hysterectomy, both ovaries remove...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00544856 — Ludwig-Maximilians - University of Munich

NCT00544856 · Ludwig-Maximilians - University of Munich
Completed Not Applicable Est. completion 1 October 2008

**Who might be able to join this trial:** - You are a man or woman aged 55 or older who has been diagnosed with Alzheimer's disease or mild cognitive impairment (a condition involving mild memory or thinking difficulties) based on recognise...

Trial: NCT05680532 — Chung Shan Medical University

NCT05680532 · Chung Shan Medical University
Completed Not Applicable Est. completion 5 June 2022
🇹🇼 TW

**Who might be able to join this trial:** - Your Body Mass Index (BMI) is 27 or higher, AND your waist measures 90cm (about 35 inches) or more if you are a man, or 80cm (about 31 inches) or more if you are a woman - Your body fat percentage...

Trial: NCT03663387 — Weill Medical College of Cornell University

NCT03663387 · Weill Medical College of Cornell University
Completed Not Applicable Est. completion 31 August 2022
🇺🇸 US

**Who might be able to join this trial:** - You are between 20 and 100 years old (younger people are not included because the condition being studied is very rare in younger age groups) - You speak English as your first language, or you are...

Trial: NCT03650816 — Assistance Publique - Hôpitaux de Paris

NCT03650816 · Assistance Publique - Hôpitaux de Paris
Completed Not Applicable Est. completion 15 February 2023
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with Alzheimer's disease based on established medical guidelines (confirm with trial site) - OR you have noticed memory or thinking problems...

Trial: NCT06039267 — George Washington University

NCT06039267 · George Washington University
Completed Not Applicable Est. completion 24 August 2025
🇺🇸 US

Who might be able to join this trial: - You are between 50 and 90 years old - You have been diagnosed with early Alzheimer's Disease - You have been diagnosed with Mild Cognitive Impairment (a condition involving slight but noticeable memor...

Trial: NCT04080544 — Neil M Rofsky, MD, MHA

NCT04080544 · Neil M Rofsky, MD, MHA
Completed Phase 2 Est. completion 30 June 2022
🇺🇸 US

**Who might be able to join this trial:** - You took part in Wave 1 or Wave 2 of a previous study called the DLBS study. - If you are a woman who could potentially become pregnant, you must confirm you are not currently pregnant and agree...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03553173 — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

NCT03553173 · Fundación Pública Andaluza para la gestión de la I...
Completed Not Applicable Est. completion 24 October 2018

"Who might be able to join this trial: - You are a smoker who is attending the Smoking Cessation Unit at "Virgen del Rocío" University Hospital. - You are over 18 years old and want to quit smoking. - You own an Android-based smartphone. -...

Trial: NCT02063308 — Russell Swerdlow, MD

NCT02063308 · Russell Swerdlow, MD
Completed Not Applicable Est. completion 1 June 2014
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with mild or moderate Alzheimer's disease - You have a study partner (such as a family member or caregiver) who can participate alongside you - English is your first or main la...

Trial: NCT02503098 — Recovery Record Research

NCT02503098 · Recovery Record Research
Completed Not Applicable Est. completion 13 July 2018
🇺🇸 US

**Who might be able to join this trial:** - You have noticeable symptoms of an eating disorder, based on answers to a self-reported questionnaire - You own an Android or iPhone smartphone and are willing to use it as part of the study - You...

Trial: NCT00329082 — Eli Lilly and Company

NCT00329082 · Eli Lilly and Company
Completed Phase 2 Est. completion 1 May 2008
🇺🇸 US

Who might be able to join this trial: - You are at least 50 years old and have been diagnosed with mild to moderate Alzheimer's disease, or you are a healthy volunteer - You are able to read and speak English fluently - If you have Alzheime...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05880849 — Paul E Schulz

NCT05880849 · Paul E Schulz
Completed Phase 1 Est. completion 1 July 2025
🇺🇸 US

**Who might be able to join this trial:** - You have signed a consent form before any study assessments begin. - You are male or female, aged between 55 and 80 years old. - You are able to understand what the study involves and have had the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03717597 — University of California, Davis

NCT03717597 · University of California, Davis
Completed Not Applicable Est. completion 31 December 2020
🇺🇸 US

Who might be able to join this trial: - You have been told by a doctor that you have subjective cognitive complaints (this means you feel you are having memory or thinking problems, even if tests don't show a clear cause) - You are 65 years...

Trial: NCT01661673 — FORUM Pharmaceuticals Inc

NCT01661673 · FORUM Pharmaceuticals Inc
Completed Phase 2 Est. completion 1 October 2013
🇺🇸 US

**Who might be able to join this trial:** - **Part 1 (Healthy Volunteers):** Men and women between 45 and 65 years old who are in good general health, have a body weight in the normal-to-moderate range (BMI 18–32), and test negative for dr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00948259 — Noscira SA

NCT00948259 · Noscira SA
Completed Phase 2 Est. completion 1 November 2009
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with probable Alzheimer's disease based on recognised medical guidelines - You are between 60 and 85 years old (those over 85 may still be considered after review by the s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00000176 — National Institute on Aging (NIA)

NCT00000176 · National Institute on Aging (NIA)
Completed Phase 3 Est. completion 1 September 2007
🇺🇸 US

Who might be able to join this trial: - You are a woman aged 65 or older who is generally in good health - You have a family history of memory problems - You are not currently taking estrogen Who may not be able to join: - You have signifi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02392468 — Boehringer Ingelheim

NCT02392468 · Boehringer Ingelheim
Completed Phase 1 Est. completion 3 August 2017
🇺🇸 US

**Who might be able to join this trial:** **If you have schizophrenia:** - You have a confirmed diagnosis of schizophrenia and have been in a stable, non-acute phase of your illness for at least 8 weeks before joining. - You have been on y...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04515433 — Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

NCT04515433 · Azienda Socio Sanitaria Territoriale degli Spedali...
Completed Not Applicable Est. completion 30 September 2020
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with mild cognitive impairment (early-stage memory and thinking difficulties) that is believed to be caused by Alzheimer's disease, based on specific medical guidelines Who ma...

Trial: NCT02410408 — Universidad Miguel Hernandez de Elche

NCT02410408 · Universidad Miguel Hernandez de Elche
Completed Not Applicable Est. completion 1 January 2016
🇪🇸 ES

Who might be able to join this trial: - You must be a staff member (confirm with trial site for details on which type of staff are eligible) Who may not be able to join: - People who have less than 3 years of experience working in healthca...

Trial: NCT00283725 — Ortho-McNeil Neurologics, Inc.

NCT00283725 · Ortho-McNeil Neurologics, Inc.
Completed Not Applicable Est. completion 1 December 2006

Who might be able to join this trial: - You have been diagnosed by a doctor with mild to moderate Alzheimer's disease, confirmed by a memory test score between 10 and 24 out of 30 - You are living at home or in an assisted living facility,...

Trial: NCT00829816 — Medivation, Inc.

NCT00829816 · Medivation, Inc.
Completed Phase 1 Est. completion 1 April 2009
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Alzheimer's disease - You are currently taking a medication called Memantine - You have a caregiver who is willing to come with you to all of your clinic appointments Who...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01450891 — Maastricht University Medical Center

NCT01450891 · Maastricht University Medical Center
Completed Not Applicable Est. completion 1 July 2013
🇳🇱 NL

**Who might be able to join this trial:** - You are a new patient at one of the participating memory clinics and doctors suspect you may have a brain condition affecting memory or thinking. - You have memory concerns, whether noticed only b...

Trial: NCT01481961 — Pierre Vandel, MD PhD

NCT01481961 · Pierre Vandel, MD PhD
Completed Not Applicable Est. completion 1 May 2012
🇫🇷 FR

"Who might be able to join this trial: - You have been diagnosed with early Alzheimer's disease or a related memory/thinking condition, based on a specific set of recognised medical guidelines. - You have been taking a type of medication us...

Trial: NCT05150990 — University of California, Santa Barbara

NCT05150990 · University of California, Santa Barbara
Completed Not Applicable Est. completion 16 March 2024
🇺🇸 US

**Who might be able to join this trial:** **For older adults:** - You must live in one of the senior living communities that is taking part in this study - You must be at least 50 years old - You must be able to speak and understand Englis...

Trial: NCT02035982 — Sunnybrook Health Sciences Centre

NCT02035982 · Sunnybrook Health Sciences Centre
Completed Phase 3 Est. completion 1 May 2014
🇨🇦 CA

**Who might be able to join this trial:** - You are older than 55 years of age - You have been diagnosed with Alzheimer's disease (a type of progressive memory and thinking condition) according to recognised medical guidelines - Your Alzhe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03418688 — Cortexyme Inc.

NCT03418688 · Cortexyme Inc.
Completed Phase 1 Est. completion 15 October 2018
🇺🇸 US

Who might be able to join this trial: - You are between 55 and 80 years old at the time you sign the consent form - If you are a man who could father children, you must agree to use two forms of birth control or avoid sex from your first do...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00658125 — University Health Network, Toronto

NCT00658125 · University Health Network, Toronto
Completed Not Applicable Est. completion 30 June 2010
🇨🇦 CA

Who might be able to join this trial: - You are a man or woman between 40 and 80 years old - You have been diagnosed with probable Alzheimer's disease (confirm with trial site for exact diagnostic criteria) - You received your Alzheimer's d...

Trial: NCT03884647 — QuantalX Neuroscience

NCT03884647 · QuantalX Neuroscience
Completed Not Applicable Est. completion 6 May 2022
🇮🇱 IL 🇺🇸 US

**Who might be able to join this trial:** - You are between 50 and 75 years old (inclusive) and are either male or female. - You have at least one risk factor for stroke or dementia — this includes things like a previous stroke or mini-stro...

Trial: NCT03049501 — University of Miami

NCT03049501 · University of Miami
Completed Not Applicable Est. completion 20 April 2018
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You speak and understand English or Spanish - You are caring for a family member or loved one who has memory problems - You do not have a terminal (life-limiting) illne...

Trial: NCT03757325 — Denali Therapeutics Inc.

NCT03757325 · Denali Therapeutics Inc.
Completed Phase 1 Est. completion 5 December 2019
🇳🇱 NL 🇺🇸 US

**Who might be able to join this trial:** - You are a man, or a woman who is not able to become pregnant, and you are between 55 and 85 years old - You have been diagnosed with Alzheimer's disease based on specific guidelines set out in 201...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01273272 — University of Zurich

NCT01273272 · University of Zurich
Completed Phase 2 Est. completion 1 September 2017
🇨🇭 CH

Who might be able to join this trial: - You must have been diagnosed with Alzheimer's disease (probable or possible), or a combination of Alzheimer's and vascular (blood vessel-related) dementia. - Your dementia must be at a mild stage, bas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01734395 — Janssen Korea, Ltd., Korea

NCT01734395 · Janssen Korea, Ltd., Korea
Completed Not Applicable Est. completion 1 January 2008

Who might be able to join this trial: - You have been diagnosed with Alzheimer's disease based on recognised medical guidelines - Your score on a standard memory and thinking test (called the K-MMSE) is between 10 and 24, indicating mild to...

Trial: NCT00088387 — National Institute of Neurological Disorders and Stroke (NINDS)

NCT00088387 · National Institute of Neurological Disorders and S...
Completed Phase 2
🇺🇸 US

Who might be able to join this trial: - You are between 40 and 90 years old (inclusive). - You have been diagnosed with Alzheimer's disease and are able to give your own consent to participate (you will be assessed for this ability). - Your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03814603 — NYU Langone Health

NCT03814603 · NYU Langone Health
Completed Not Applicable Est. completion 31 May 2025
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman between 60 and 75 years old with normal memory and thinking abilities. - Your neurological (brain and nervous system) and mental health check-ups are within normal ranges, w...

Trial: NCT06217237 — IRCCS Centro Neurolesi Bonino Pulejo

NCT06217237 · IRCCS Centro Neurolesi Bonino Pulejo
Completed Not Applicable Est. completion 22 December 2020
🇮🇹 IT

**Who might be able to join this trial:** **For patients:** - Your cognitive decline started no more than 24 months ago - Your score on a standard memory and thinking test (CDR) is 2 or lower - Your score on another thinking and memory tes...

Trial: NCT00439166 — Hamilton Health Sciences Corporation

NCT00439166 · Hamilton Health Sciences Corporation
Completed Phase 3 Est. completion 1 April 2010
🇨🇦 CA

Who might be able to join this trial: - You can be either male or female - You must be 50 years old or older - You have been diagnosed with probable Alzheimer's disease (based on a specific set of medical guidelines called NINCDS-ADRDA crit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01202994 — University of Utah

NCT01202994 · University of Utah
Completed Phase 2 Est. completion 1 May 2016
🇺🇸 US

**Who might be able to join this trial:** - You are currently taking part in a separate NIA (National Institute on Aging)-funded community study about memory and thinking skills in older adults aged 65 and over who live independently and do...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03863041 — Poitiers University Hospital

NCT03863041 · Poitiers University Hospital
Completed Not Applicable Est. completion 15 June 2023
🇫🇷 FR

**Who might be able to join this trial:** - You have memory concerns that led you to visit a specialist memory clinic (in Poitiers), and your doctors have recommended an MRI scan as part of your regular care - You are under 90 years old - Y...

Trial: NCT01993836 — Duke University

NCT01993836 · Duke University
Completed Phase 4 Est. completion 10 January 2019
🇺🇸 US

Who might be able to join this trial: - You are 60 years of age or older and are having surgery - Your surgery is expected to last at least 2 hours, including the time needed for preparation and anesthesia - You are able to speak and unders...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05292248 — Case Western Reserve University

NCT05292248 · Case Western Reserve University
Completed Not Applicable Est. completion 15 December 2023
🇺🇸 US

Who might be able to join this trial: - You are a caregiver for a family member or loved one who was diagnosed by a doctor with Alzheimer's disease or a related form of dementia at least 6 months ago - You identify as Latino or Hispanic - Y...

Trial: NCT00416078 — US Department of Veterans Affairs

NCT00416078 · US Department of Veterans Affairs
Completed Phase 3 Est. completion 1 June 2012
🇺🇸 US

Who might be able to join this trial: - The patient lives in the community (not in a care home or facility) and is able to get around. - The patient has been diagnosed with Alzheimer's disease. - The patient is between 50 and 95 years old....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04305652 — Aksaray University

NCT04305652 · Aksaray University
Completed Not Applicable Est. completion 20 November 2020
Turkey (Türkiye)

**Who might be able to join this trial:** - You must be 18 years old or older - You must be caring for someone with mild to moderate Alzheimer's disease (their memory/thinking test score is 19 or below out of 30) - You must be a close famil...

Trial: NCT03370744 — XuanwuH 2

NCT03370744 · XuanwuH 2
Completed Not Applicable Est. completion 30 June 2020
🇨🇳 CN

**Who might be able to join this trial:** **Normal Cognition (NC) group:** - You are older than 60, right-handed, and of Han Chinese nationality - You have no concerns or worries about your own memory or thinking ability - Your results on...

Trial: NCT02236663 — Johns Hopkins University

NCT02236663 · Johns Hopkins University
Completed Not Applicable Est. completion 1 October 2017
🇺🇸 US

**Who might be able to join this trial:** - You are a woman who is currently experiencing physical violence, sexual violence, emotional abuse, or stalking from a current or former romantic partner - You are a woman or man who has a female f...

Trial: NCT01018875 — AbbVie (prior sponsor, Abbott)

NCT01018875 · AbbVie (prior sponsor, Abbott)
Completed Phase 2 Est. completion 1 February 2011
🇷🇺 RU 🇺🇦 UA

**Who might be able to join this trial:** - You have agreed to take part willingly and signed a consent form. - You have been diagnosed with probable Alzheimer's Disease (AD). - If you are female, you have been through menopause for at leas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06803797 — Northwell Health

NCT06803797 · Northwell Health
Completed Not Applicable Est. completion 14 May 2026
🇺🇸 US

Who might be able to join this trial: - You are a caregiver (either paid/professional or unpaid/family or friend) for someone living with Alzheimer's disease or a related form of dementia - You are between 18 and 85 years old - Your primary...

Trial: NCT07417670 — Carnot Laboratories

NCT07417670 · Carnot Laboratories
Completed Phase 4 Est. completion 12 August 2025
🇲🇽 MX

Who might be able to join this trial: - You have been formally diagnosed with Alzheimer's disease using recognised medical guidelines. - Your Alzheimer's disease is at a moderate to severe stage, confirmed by specific memory and thinking te...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01662882 — Avid Radiopharmaceuticals

NCT01662882 · Avid Radiopharmaceuticals
Completed Phase 3 Est. completion 1 February 2013
🇯🇵 JP

Who might be able to join this trial: **If you have Alzheimer's disease (AD):** - You are Japanese, male or female, and at least 50 years old, with a formal diagnosis of probable Alzheimer's disease - You have mild to moderate memory/think...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03246269 — Andreas Monsch

NCT03246269 · Andreas Monsch
Completed Not Applicable Est. completion 1 April 2017

Who might be able to join this trial: - You are 65 years of age or older - You have completed at least 7 years of formal education - You are fluent in the German language - You are able and willing to sign a written consent form to take par...

Trial: NCT05395559 — University Medical Center Groningen

NCT05395559 · University Medical Center Groningen
Completed Not Applicable Est. completion 21 September 2022
🇳🇱 NL

Who might be able to join this trial: - You speak Dutch - You are currently staying in hospital - You are 65 years old or older Who may not be able to join: - You are unable to complete a short memory and thinking test called the Mini-Cog,...

Trial: NCT01630525 — University Hospital, Bordeaux

NCT01630525 · University Hospital, Bordeaux
Completed Not Applicable Est. completion 1 December 2015
🇫🇷 FR

**Who might be able to join this trial:** - You must be older than 60 years of age - You must have good enough vision (with glasses or contacts if needed) to see clearly with both eyes - You must be willing and able to sign a consent form...

Trial: NCT03071224 — Invicro

NCT03071224 · Invicro
Completed Early Phase 1 Est. completion 9 June 2021
🇺🇸 US

**Who might be able to join this trial:** **For everyone in the trial:** - You must be willing and able to sign a consent form before anything begins - Women must either be surgically unable to have children (through hysterectomy, removal...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05215782 — Optina Diagnostics Inc.

NCT05215782 · Optina Diagnostics Inc.
Completed Not Applicable Est. completion 16 March 2023
🇺🇸 US

**Who might be able to join this trial:** - You are between 50 and 90 years old (male or female) - You or someone who knows you well has noticed memory or thinking problems, and a doctor is currently looking into whether Alzheimer's diseas...

Trial: NCT05643326 — Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

NCT05643326 · Azienda Socio Sanitaria Territoriale degli Spedali...
Completed Not Applicable Est. completion 15 October 2024
🇮🇹 IT

**Who might be able to join this trial:** *For patients:* - You have been diagnosed with mild Alzheimer's disease, based on a standard rating scale score between 0.5 and 1 (known as CDR) *For caregivers:* - You are 18 years old or older -...

Trial: NCT04583033 — University of Miami

NCT04583033 · University of Miami
Completed Not Applicable Est. completion 31 October 2023
🇺🇸 US

**Who might be able to join this trial:** - You are 55 years of age or older - You speak English - You are willing and able to agree to take part in the study - Your thinking and memory are considered normal (no signs of cognitive problems)...